Imunon, Inc. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Imunon, Inc. (IMNN) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $13.37 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2024-03-28
- Imunon, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2018-12-31 was $0.00.
- Imunon, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2018-09-30 was $4.51M, a 78.97% increase year-over-year.
- Imunon, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2017-12-31 was $0.00.
- Imunon, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2017-09-30 was $2.52M.
- Imunon, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $13.37M.
- Imunon, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2018 was $4.51M, a 78.97% increase from fiscal 2017.
- Imunon, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2017 was $2.52M, a 74.51% increase from fiscal 2016.
- Imunon, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2016 was $1.44M.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2022-12-31 | $13.37M 10-K · filed 2024-03-28 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $4.51M derived: sum of 2 quarters · filed 2019-03-29 | $4.51M 10-K · filed 2019-03-29 | |
| 2018-09-30 | $4.51M 10-Q · filed 2018-11-14 | $4.51M 10-Q · filed 2018-11-14 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $2.52M derived: sum of 2 quarters · filed 2019-03-29 | $5.04M derived: sum of 3 quarters · filed 2019-03-29 | $2.52M 10-K · filed 2019-03-29 |
| 2017-09-30 | $2.52M 10-Q · filed 2017-11-14 | $5.04M derived: sum of 2 quarters · filed 2018-11-14 | $2.52M 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $2.52M 10-Q · filed 2018-11-14 | |||
| 2016-12-31 | $1.44M 10-K · filed 2018-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |